Immunotherapies and Novel Targeted Agents in NSCLC
An Oncology Exchange Initiative
A series of Live Grand Rounds Programs
Welcome to "Immunotherapies and Novel Targeted Agents in NSCLC." This CME-certified initiative is intended for community-based oncologists, oncology nurses, and other healthcare professionals involved in the care of patients with NSCLC. A series of live CME-certified programs will be presented at selected hospitals throughout the US during 2016.
The expanding treatment landscape for non-small cell lung cancer (NSCLC) necessitates updates for community oncologists to ensure they are well-versed with the mechanisms of action of novel targeted agents and their roles in personalizing treatments for NSCLC. Community oncologists must stay up to date with recent clinical data from studies of immunotherapies, treatment options for patients with anaplastic lymphoma kinase positive (ALK+) disease who develop resistance to ALK inhibitors, and other novel targeted agents.
Immunotherapies and Novel Targeted Agents in NSCLC will educate community clinicians on the most recent advances in the management of NSCLC and provide tools to better engage their patients in treatment decisions.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
Assess the indications and management of immunotherapeutic agents that are approved or under investigation in NSCLC
Evaluate the current and emerging targeted agents for NSCLC
Empower patients to become active participants in their treatment decisions and health management
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please email email@example.com.
Calendars for Live Activities
If you are interested in attending a meeting in your local area, please contact Kathy Whyte at 443-909-7901 or firstname.lastname@example.org for the schedule.
A calendar of live events, as well as additional CME/CE-certified online activities, for this and other Oncology Exchange programming, can be found at: http://www.medscape.org/sites/advances/oncologyexchange.
Click here to access the CME-certified webcourse associated with this program. (Coming soon)
Live Program Materials for Speakers and Administrators
Back to Top
I. Administrator Material
II. Speaker Material
Thank you for joining us as an expert speaker for the 2016 Grand Rounds series, “Immunotherapies and Novel Targeted Agents in NSCLC.” This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:
Indications and management of immunotherapeutic agents that are approved or under investigation in NSCLC
Current and emerging targeted agents for NSCLC
How to empower patients to become active participants in their treatment decisions and health management
Transcript of Speaker Orientation Download (PDF)
Audio download of Speaker Orientation
CME-certified Program Slides
This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint)
All steering committee and speaking faculty disclosures will be provided onsite in program syllabi distributed to all grand rounds participants.
Joel Neal, MD, PhD
Assistant Professor of Medicine (Oncology)
Stanford University School of Medicine
Joel Neal, MD, PhD earned a medical degree and a doctoral degree in tumor cell biology from the Feinberg School of Medicine at Northwestern University in Chicago, IL. He then completed a fellowship in oncology at Dana-Farber Cancer Institute/Massachusetts General Hospital Cancer Center in Boston, MA. He is currently an Assistant Professor of Medicine (Oncology) at the Stanford Cancer Institute at Stanford University in Palo Alto, CA. He is an active member of the Eastern Cooperative Oncology Group and the American Society of Clinical Oncology. Dr. Neal’s primary clinical interest is thoracic oncology and, in addition to patient care, he focuses on the design and execution of clinical trials involving targeted therapies for lung cancer.
Taofeek K. Owonikoko, MD, PhD, MSCR
GRA Distinguished Cancer Scientist
Co-chair, Clinical and Translational Research Committee
Associate Director, Hematology/Oncology Fellowship Training Program
Emory University Winship Cancer Institute
Taofeek K. Owonikoko, MD, PhD, MSCR is an Associate Professor in the Department of Hematology and Medical Oncology at Emory University and a Distinguished Cancer Scientist designated by the Georgia Research Alliance. He received his primary medical training at the Obafemi Awolowo University in Ile-Ife, Nigeria and obtained his doctoral degree in anatomic pathology from the Heinrich Heine University in Dusseldorf, Germany. He was a postdoctoral research fellow at Johns Hopkins University in Baltimore, MD from 2000-2002, then completed residency training in internal medicine at the Graduate Hospital at Drexel University in Philadelphia, PA. He later completed a clinical fellowship in hematology/medical oncology at the University of Pittsburgh.
Dr. Owonikoko has been on the faculty at Emory University since 2008 and has focused his translational research activities on lung cancer and head and neck cancer, as well in early drug development. He has been a direct recipient and collaborator on several grants funded by the National Institutes of Health, the Department of Defense, and the Georgia Cancer Coalition. He has also received research funding in support of his investigator-initiated clinical trials from pharmaceutical industry collaborators. He has published more than 90 peer-reviewed manuscripts in high-impact journals, such as Cell, CA Cancer Journal, Cancer Cell, Nature Communications, Journal of Clinical Oncology, Oncogene, Cancer Research, Clinical Cancer Research, Cancer, The Oncologist, and Journal of Thoracic Oncology.